Business Description
Liquidia Corporation is a US-based medicine company focused on treating rare lung and heart conditions, particularly pulmonary arterial hypertension and related diseases. Its main products include YUTREPIA, an inhaled powder treatment, and Remodulin, a continuous infusion therapy, with a further treatment called L606 currently in late-stage clinical trials. The company also owns a proprietary particle engineering technology that gives precise control over the size, shape, and makeup of drug particles, which supports both its own products and partnerships with other organizations. Founded in 2004 and headquartered in Morrisville, North Carolina, Liquidia works with several partners including Pharmosa Biopharm and Sandoz to expand the reach of its treatments.
